HTB | HIV i-Base

Further news from IAS 2023, semaglutide in HIV and more

Featured HTB September/October 2023 1 September 2023. Related: Editorial.
Featured HTB May/June 2023: HIV and implementation science 1 June 2023. Related: Editorial.
Featured HTB April 2023 (6 April 2023) 6 April 2023. Related: Editorial.
Featured HTB March 2023 (10 March 2023) 10 March 2023. Related: Editorial.
Featured HTB January/February 2023 (1 February 2023) 1 February 2023. Related: Editorial.
Featured In memory: Timothy Ray Brown – the Berlin patient, the first person to be cured of HIV 14 October 2020. Related: In memory.
HTB October/November 2023 1 October 2023. Related: Editorial.
12th IAS Conference on HIV Science (IAS 2023): further reports 1 October 2023. Related: Conference reports, Conference index, IAS 2023 Brisbane.
Uganda report: LGBT+ assaults and human rights violations increase 1 October 2023. Related: Editorial, Special reports, Treatment advocacy, Other news.
IAS 2023: Lenacapavir studies at IAS: weekly oral dosing and baseline sensitivity in non-clade B settings 1 October 2023. Related: Conference reports, Antiretrovirals, IAS 2023 Brisbane.
IAS 2023: LA-CAB/RPV as first-line ART and implementation studies 1 October 2023. Related: Conference reports, Antiretrovirals.
IAS 2023: bNAbs for prevention and cure: antiviral and vaccine-like responses 1 October 2023. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Cure research, Vaccines and microbicides, IAS 2023 Brisbane.
IAS 2023: High rates of re-suppression with dolutegravir in the ADVANCE study 1 October 2023. Related: Conference reports, Treatment strategies, Drug resistance, IAS 2023 Brisbane.
IAS 2023: Bictegravir use in pregnancy: more data needed 1 October 2023. Related: Conference reports, Pregnancy.
IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density 1 October 2023. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission, IAS 2023 Brisbane.
UK surveys on access to New-Fill for facial lipoatrophy 1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.
>10% weight gain during first two years of ART linked to double the risk of cardiometabolic disease 1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.
EU approves cabotegravir as injectable PrEP 1 October 2023. Related: HIV prevention and transmission.
Altered kidney function associated with alcohol and cannabis use by women living with HIV 1 October 2023. Related: Side effects.
Early phase 1 HIV vaccine study launched in the US and South Africa 1 October 2023. Related: Vaccines and microbicides.
Mutations associated with resistance to dapivirine vaginal ring: reported in 7/38 women seroconverting in the open-label HOPE study 1 October 2023. Related: HIV prevention and transmission.
Future meetings and webinars 2023/24 1 October 2023. Related: Future meetings.
HTB: no. 10/11 (Oct/Nov 2023) PDF download 1 October 2023. Related: PDFs.
Defective HIV proviral particles linked to persistent inflammation and immune activation despite effective ART 1 September 2023. Related: Pathogenesis, Basic science and immunology.
HTB: no. 9 (Sept 2023) PDF download 1 September 2023. Related: PDFs.
12th IAS Conference on HIV Science (IAS 2023): further reports 1 September 2023. Related: Conference reports, IAS 2023 Brisbane.
Non-technical summary of articles in HTB September/October 2023 1 September 2023. Related: Editorial.
IAS 2023: Update to navigating the programme and online access 1 September 2023. Related: Conference reports, IAS 2023 Brisbane.
IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data 1 September 2023. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, IAS 2023 Brisbane.
IAS 2023: CHAPAS-4 supports better second-line options for children 1 September 2023. Related: Conference reports, Paediatric care.
IAS 2023: Rapporteur summary track A – basic science 1 September 2023. Related: Conference reports, Cure research, Basic science and immunology, Vaccines and microbicides, IAS 2023 Brisbane.
IAS 2023: Rapporteur summary track C – prevention 1 September 2023. Related: Conference reports, HIV prevention and transmission, IAS 2023 Brisbane.
IAS 2023: Rapporteur summary track D – social and behavioural science 1 September 2023. Related: Conference reports, Treatment strategies, IAS 2023 Brisbane.
Timing of ART with cryptococcus: Europe and the US cohort data challenged by African RCT data and editorial comment 1 September 2023. Related: Coinfections and complications.
Cannabis does not reduce T cells in people living with HIV 1 September 2023. Related: Pathogenesis, Basic science and immunology.
Peripheral inflammation linked to structural brain changes and reduced blood flow despite suppressive ART 1 September 2023. Related: Coinfections and complications.
Tecovirimat resistance in a person with advanced HIV and delayed ART 1 September 2023. Related: mpox (monkeypox).
Breakthrough HIV infection on PrEP with injectable cabotegravir 6 August 2023. Related: HIV prevention and transmission, CROI 30 (Retrovirus) 2023.
HTB July/August 2023 1 August 2023. Related: Editorial.
Non technical HTB: 11 stories from July/August 1 August 2023. Related: Editorial.
12th IAS Conference on HIV Science (IAS 2023) 1 August 2023. Related: Conference reports, IAS 2023 Brisbane.
IAS 2023: Update to navigate the programme and online access 1 August 2023. Related: Conference reports, IAS 2023 Brisbane.
WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load 1 August 2023. Related: Conference reports, Treatment strategies, HIV prevention and transmission, IAS 2023 Brisbane.
Viral load level when suppressed <1000 predicts future rebound: 3-monthly monitoring required 1 August 2023. Related: Conference reports, HIV prevention and transmission, IAS 2023 Brisbane.
ART-associated hypertension can be successfully treated in African settings 1 August 2023. Related: Conference reports, Side effects, Coinfections and complications, IAS 2023 Brisbane.
REPRIEVE study: statin benefits people living with HIV at low to moderate CVD risk 1 August 2023. Related: Conference reports, Coinfections and complications, IAS 2023 Brisbane.
Geneva patient and other HIV cure research at IAS 2023 1 August 2023. Related: Conference reports, Cure research, IAS 2023 Brisbane.
Guide to other HIV cure-related research at IAS 2023 1 August 2023. Related: Conference reports, IAS 2023 Brisbane.
Rapporteur summaries: track B clinical science 1 August 2023. Related: Conference reports, Antiretrovirals, IAS 2023 Brisbane.
Early press conference: cure, gay circumcision, PrEP choices, mpox, and COVID-19 1 August 2023. Related: Conference reports, mpox (monkeypox), HIV prevention and transmission, Cure research, COVID-19: HIV and COVID-19 coinfection, COVID-19, IAS 2023 Brisbane.
High rates of occult HBV in Botswana: risks from relying on HBsAg screening 1 August 2023. Related: Conference reports, Hepatitis coinfection, IAS 2023 Brisbane.
Anal cancer: 1 in 5 risk of missing precancerous lesions if only HSIL are biopsied 1 August 2023. Related: Conference reports, Cancer and HIV, IAS 2023 Brisbane.
BHIVA Annual Conference 2023 (BHIVA 2023) – final reports 1 August 2023. Related: Conference reports, Conference index, BHIVA Gateshead 2023.
No vertical HIV transmissions in the UK from women eligible for supported breastfeeding 1 August 2023. Related: Conference reports, Pregnancy, Paediatric care, BHIVA Gateshead 2023.
Adverse birth outcomes with diabetes and hypertensive disorders in pregnancy 1 August 2023. Related: Conference reports, Pregnancy, BHIVA Gateshead 2023.